Neuropathy due to bi-allelic SH3TC2 variants: genotype-phenotype correlation and natural history.
CMT4C
Charcot-Marie-Tooth disease
genotype-phenotype
longitudinal
natural history
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
05
10
2022
revised:
23
02
2023
accepted:
05
03
2023
pmc-release:
22
03
2024
medline:
5
9
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. Clear relationships between pathogenic variants and the spectrum of disease manifestations are to date lacking. Gene replacement therapy has been shown to ameliorate the phenotype in a mouse model of CMT4C, emphasizing the need for natural history studies to inform clinical trial readiness. Data, including both genetic information and clinical characteristics, were compiled from the longitudinal, prospective dataset of the Inherited Neuropathy Consortium, a member of the Rare Diseases Clinical Research Network (INC-RDCRN). The Charcot Marie Tooth Neuropathy Score (CMTNS), Examination Score (CMTES) and the Rasch-weighted CMTES (CMTES-R) were used to describe symptoms, neurological examinations and neurophysiological characteristics. Standardized response means were calculated at yearly intervals and a mixed model for repeated measures was used to estimate the change in CMTES and CMTES-R over time. Fifty-six individuals (59% female), median age 27 years (range 2-67 years) with homozygous or compound heterozygous variants in SH3TC2 were identified, including 34 unique variants, 14 of which have not previously been published. Twenty-eight participants had longitudinal data available. While there was no significant difference in the CMTES in those with protein truncating versus non-protein truncating variants, there were significant differences in the mean ulnar nerve compound muscle action potential amplitude, the mean radial sensory nerve action potential amplitude, and in the prevalence of scoliosis, suggesting the possibility of a milder phenotype in individuals with one or two non-protein-truncating variants. Overall, the mean value of the CMTES was 13, reflecting moderate clinical severity. There was a high rate of scoliosis (81%), scoliosis surgery (36%), and walking difficulty (94%) among study participants. The CMTES and CMTES-R appeared moderately responsive to change over extended follow-up, demonstrating a standardized response mean of 0.81 standard deviation units or 0.71 standard deviation units, respectively, over 3 years. Our analysis represents the largest cross-sectional and only longitudinal study to date, of the clinical phenotype of both adults and children with CMT4C. With the promise of upcoming genetic treatments, these data will further define the natural history of the disease and inform study design in preparation for clinical trials.
Identifiants
pubmed: 36947133
pii: 7083729
doi: 10.1093/brain/awad095
pmc: PMC10473553
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3826-3835Subventions
Organisme : NINDS NIH HHS
ID : K08 NS102509
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS007338
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS065712
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Hum Mol Genet. 2009 Dec 1;18(23):4603-14
pubmed: 19744956
Ann Neurol. 2012 May;71(5):642-52
pubmed: 22522479
J Peripher Nerv Syst. 2016 Sep;21(3):142-9
pubmed: 27231023
Neuromuscul Disord. 2008 Jun;18(6):483-92
pubmed: 18511281
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934
Neurology. 2010 Aug 24;75(8):726-31
pubmed: 20733147
Acta Neurol Belg. 2022 Oct;122(5):1169-1175
pubmed: 33587240
Neuromuscul Disord. 2006 Jul;16(7):449-53
pubmed: 16806930
Neuromuscul Disord. 2009 Apr;19(4):264-9
pubmed: 19272779
Muscle Nerve. 2018 May;57(5):749-755
pubmed: 28981955
Am J Hum Genet. 2003 Nov;73(5):1106-19
pubmed: 14574644
Hum Mol Genet. 2019 Nov 1;28(21):3528-3542
pubmed: 31411673
Brain. 2019 May 1;142(5):1227-1241
pubmed: 30907403
Ann Neurol. 2017 Sep;82(3):353-359
pubmed: 28796392
Neurology. 2005 Apr 12;64(7):1209-14
pubmed: 15824348
Hum Mutat. 2015 Oct;36(10):950-6
pubmed: 26173844
Clin Genet. 2013 Jun;83(6):565-70
pubmed: 22978647
Neurol Sci. 2008 Jun;29(3):157-62
pubmed: 18612763
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cell Rep. 2017 Mar 28;18(13):3178-3191
pubmed: 28355569
Muscle Nerve. 2015 Sep;52(3):444-9
pubmed: 25737037
J Neuromuscul Dis. 2019;6(2):201-211
pubmed: 30958311
Hum Mol Genet. 2010 Mar 15;19(6):1009-18
pubmed: 20028792
JAMA Neurol. 2016 Jun 1;73(6):645-51
pubmed: 27043305
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
J Neurol Sci. 2019 Nov 15;406:116376
pubmed: 31634715
Neurology. 2020 Mar 3;94(9):e884-e896
pubmed: 32047073
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17528-33
pubmed: 19805030
Neurology. 2006 Aug 22;67(4):602-6
pubmed: 16924012
Brain. 2010 Aug;133(Pt 8):2462-74
pubmed: 20826437
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669